Autonomix Medical, Inc. Announces Closing of $10.0 Million Underwritten Public Offering Including Partial Exercise of Over-Allotment Option

Core Viewpoint - Autonomix Medical, Inc. has successfully closed a public offering of common stock and pre-funded warrant units, raising approximately $10.0 million to support its clinical trials and research initiatives [1][3]. Group 1: Offering Details - The equity offering consisted of 615,500 common stock units and 917,596 pre-funded warrant units, priced at $6.54 and $6.539 per unit respectively [2]. - Each common stock unit and pre-funded warrant unit included one share of common stock and one Series A Warrant, which has an exercise price of $6.54 and expires five years from issuance [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for funding clinical trials, research and development, intellectual property development, and working capital [3]. Group 3: Company Overview - Autonomix Medical is focused on innovative technologies for diagnosing and treating diseases of the nervous system, featuring a catheter-based microchip sensing array with significantly enhanced sensitivity [6]. - The company is initially targeting pain management, particularly for pancreatic cancer, and aims to address various conditions across a wide disease spectrum [7].